Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2013 1
2015 1
2017 2
2018 2
2019 1
2020 2
2021 4
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.
Mastini C, Campisi M, Patrucco E, Mura G, Ferreira A, Costa C, Ambrogio C, Germena G, Martinengo C, Peola S, Mota I, Vissio E, Molinaro L, Arigoni M, Olivero M, Calogero R, Prokoph N, Tabbò F, Shoji B, Brugieres L, Geoerger B, Turner SD, Cuesta-Mateos C, D'Aliberti D, Mologni L, Piazza R, Gambacorti-Passerini C, Inghirami GG, Chiono V, Kamm RD, Hirsch E, Koch R, Weinstock DM, Aster JC, Voena C, Chiarle R. Mastini C, et al. Among authors: cuesta mateos c. Sci Transl Med. 2023 Jun 28;15(702):eabo3826. doi: 10.1126/scitranslmed.abo3826. Epub 2023 Jun 28. Sci Transl Med. 2023. PMID: 37379367
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Marcos-Jiménez A, Carvoeiro DC, Ruef N, Cuesta-Mateos C, Roy-Vallejo E, Gómez-García de Soria V, Laganá C, Del Campo L, Zubiaur P, Villapalos-García G, Abad-Santos F, Stein JV, Muñoz-Calleja C. Marcos-Jiménez A, et al. Among authors: cuesta mateos c. Blood Adv. 2023 Jun 13;7(11):2418-2430. doi: 10.1182/bloodadvances.2022009279. Blood Adv. 2023. PMID: 36583674 Free PMC article.
Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease.
Cuesta-Mateos C, Portero-Sainz I, García-Peydró M, Alcain J, Fuentes P, Juárez-Sánchez R, Pérez-García Y, Mateu-Albero T, Díaz-Fernández P, Vega-Piris L, Sánchez-López BA, Marcos-Jiménez A, Cardeñoso L, Gómez-García de Soria V, Toribio ML, Muñoz-Calleja C. Cuesta-Mateos C, et al. Bone Marrow Transplant. 2020 Oct;55(10):1935-1945. doi: 10.1038/s41409-020-0830-8. Epub 2020 Feb 21. Bone Marrow Transplant. 2020. PMID: 32086495
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Cuesta-Mateos C, Fuentes P, Schrader A, Juárez-Sánchez R, Loscertales J, Mateu-Albero T, Vega-Piris L, Espartero-Santos M, Marcos-Jimenez A, Sánchez-López BA, Pérez-García Y, Jungherz D, Oberbeck S, Wahnschaffe L, Kreutzman A, Andersson EI, Mustjoki S, Faber E, Urzainqui A, Fresno M, Stamatakis K, Alfranca A, Terrón F, Herling M, Toribio ML, Muñoz-Calleja C. Cuesta-Mateos C, et al. Biomark Res. 2020 Oct 24;8:54. doi: 10.1186/s40364-020-00234-z. eCollection 2020. Biomark Res. 2020. PMID: 33110606 Free PMC article.
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
Mateu-Albero T, Juárez-Sánchez R, Loscertales J, Mol W, Terrón F, Muñoz-Calleja C, Cuesta-Mateos C. Mateu-Albero T, et al. Among authors: cuesta mateos c. Cancer Immunol Immunother. 2022 Mar;71(3):627-636. doi: 10.1007/s00262-021-03014-2. Epub 2021 Jul 23. Cancer Immunol Immunother. 2022. PMID: 34297159
18 results